ALGORX PHARMACEUTICALS INC 3
3 · ALGORX PHARMACEUTICALS INC · Filed Feb 10, 2005
Insider Transaction Report
Form 3
COHEN CHARLES
Director
Holdings
- (indirect: see footnote)
Series C Preferred Stock
Exercise: $0.00→ Common Stock (20,349 underlying)
Footnotes (2)
- [F1]Each share of Series C Preferred Stock shall be automatically converted into Common Stock upon the closing of the Issuer's initial public offering and has no expiration date.
- [F2]Shares are indirectly beneficially owned as a limited partner of Advent Partners HLS III Limited Partnership.